Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 107

1.

The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma.

Zhao X, Little P, Hoyle AP, Pegna GJ, Hayward MC, Ivanova A, Parker JS, Marron DL, Soloway MG, Jo H, Salazar AH, Papakonstantinou MP, Bouchard DM, Jefferys SR, Hoadley KA, Ollila DW, Frank JS, Thomas NE, Googe PB, Ezzell AJ, Collichio FA, Lee CB, Earp HS, Sharpless NE, Hugo W, Wilmott JS, Quek C, Waddell N, Johansson PA, Thompson JF, Hayward NK, Mann GJ, Lo RS, Johnson DB, Scolyer RA, Hayes DN, Moschos SJ.

Front Oncol. 2019 Jan 4;8:584. doi: 10.3389/fonc.2018.00584. eCollection 2018.

2.

Identification of a Robust Methylation Classifier for Cutaneous Melanoma Diagnosis.

Conway K, Edmiston SN, Parker JS, Kuan PF, Tsai YH, Groben PA, Zedek DC, Scott GA, Parrish EA, Hao H, Pearlstein MV, Frank JS, Carson CC, Wilkerson MD, Zhao X, Slater NA, Moschos SJ, Ollila DW, Thomas NE.

J Invest Dermatol. 2018 Dec 6. pii: S0022-202X(18)32916-6. doi: 10.1016/j.jid.2018.11.024. [Epub ahead of print]

PMID:
30529013
3.

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.

Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, Atkins MB, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Thomas RP, Tarhini A, Pavlick AC, Jiang J, Avila A, Demelo S, Margolin K.

N Engl J Med. 2018 Aug 23;379(8):722-730. doi: 10.1056/NEJMoa1805453.

4.

Extracellular vesicles and their nucleic acids for biomarker discovery.

Momen-Heravi F, Getting SJ, Moschos SA.

Pharmacol Ther. 2018 Dec;192:170-187. doi: 10.1016/j.pharmthera.2018.08.002. Epub 2018 Aug 3. Review.

PMID:
30081050
5.

A novel antifungal property for the Bacillus licheniformis ComX pheromone and its possible role in inter-kingdom cross-talk.

Esmaeilishirazifard E, Dariush A, Moschos SA, Keshavarz T.

Appl Microbiol Biotechnol. 2018 Jun;102(12):5197-5208. doi: 10.1007/s00253-018-9004-7. Epub 2018 Apr 23.

PMID:
29687141
6.

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors.

Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC, Shapira-Frommer R, Tawbi HA, Rubino J, Rush TS 3rd, Zhang D, Miselis NR, Samatar AA, Chun P, Rubin EH, Schiller J, Long BJ, Dayananth P, Carr D, Kirschmeier P, Bishop WR, Deng Y, Cooper A, Shipps GW, Moreno BH, Robert L, Ribas A, Flaherty KT.

JCI Insight. 2018 Feb 22;3(4). pii: 92352. doi: 10.1172/jci.insight.92352. eCollection 2018 Feb 22.

7.

Profiling the Mismatch Tolerance of Argonaute 2 through Deep Sequencing of Sliced Polymorphic Viral RNAs.

Theotokis PI, Usher L, Kortschak CK, Schwalbe E, Moschos SA.

Mol Ther Nucleic Acids. 2017 Dec 15;9:22-33. doi: 10.1016/j.omtn.2017.08.010. Epub 2017 Aug 24.

8.

Oligonucleotide Therapies for the Lung: Ready to Return to the Clinic?

Kumar M, Moschos SA.

Mol Ther. 2017 Dec 6;25(12):2604-2606. doi: 10.1016/j.ymthe.2017.11.002. Epub 2017 Nov 23. No abstract available.

9.

Field-deployable, quantitative, rapid identification of active Ebola virus infection in unprocessed blood.

Shah K, Bentley E, Tyler A, Richards KSR, Wright E, Easterbrook L, Lee D, Cleaver C, Usher L, Burton JE, Pitman JK, Bruce CB, Edge D, Lee M, Nazareth N, Norwood DA, Moschos SA.

Chem Sci. 2017 Nov 1;8(11):7780-7797. doi: 10.1039/c7sc03281a. Epub 2017 Sep 25.

10.

Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity.

Bakhru P, Zhu ML, Wang HH, Hong LK, Khan I, Mouchess M, Gulati AS, Starmer J, Hou Y, Sailer D, Lee S, Zhao F, Kirkwood JM, Moschos S, Fong L, Anderson MS, Su MA.

JCI Insight. 2017 Sep 21;2(18). pii: 93265. doi: 10.1172/jci.insight.93265. eCollection 2017 Sep 21.

11.

Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, Meyer N, Zhang Y, Huang Y, Mookerjee B, Long GV.

Lancet Oncol. 2017 Jul;18(7):863-873. doi: 10.1016/S1470-2045(17)30429-1. Epub 2017 Jun 4.

12.

Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-α2b in patients with metastatic melanoma.

Tarhini AA, Moschos SJ, Lin Y, Lin HM, Sander C, Yin Y, Venhaus R, Gajewski TF, Kirkwood JM.

Melanoma Res. 2017 Aug;27(4):342-350. doi: 10.1097/CMR.0000000000000353.

PMID:
28489678
13.

Genomic and molecular characterization of a novel quorum sensing molecule in Bacillus licheniformis.

Esmaeilishirazifard E, De Vizio D, Moschos SA, Keshavarz T.

AMB Express. 2017 Dec;7(1):78. doi: 10.1186/s13568-017-0381-6. Epub 2017 Apr 8.

14.

The incidence of radiation necrosis following stereotactic radiotherapy for melanoma brain metastases: the potential impact of immunotherapy.

Kaidar-Person O, Zagar TM, Deal A, Moschos SJ, Ewend MG, Sasaki-Adams D, Lee CB, Collichio FA, Fried D, Marks LB, Chera BS.

Anticancer Drugs. 2017 Jul;28(6):669-675. doi: 10.1097/CAD.0000000000000497.

PMID:
28368903
15.

Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.

Salama AK, Moschos SJ.

Ann Oncol. 2017 Jan 1;28(1):57-74. doi: 10.1093/annonc/mdw534. Review.

PMID:
28177433
16.

Exceptional Chemotherapy Response in Metastatic Colorectal Cancer Associated With Hyper-Indel-Hypermutated Cancer Genome and Comutation of POLD1 and MLH1.

Sharma MR, Auman JT, Patel NM, Grilley-Olson JE, Zhao X, Moschos SJ, Parker JS, Yin X, Hayward MC, Polite BN, Marangon E, Posocco B, Toffoli G, Hayes DN, Innocenti F.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.16.00015. Epub 2017 Apr 27.

17.

Clinical potential of oligonucleotide-based therapeutics in the respiratory system.

Moschos SA, Usher L, Lindsay MA.

Pharmacol Ther. 2017 Jan;169:83-103. doi: 10.1016/j.pharmthera.2016.10.009. Epub 2016 Oct 19. Review.

PMID:
27771436
18.

Melanoma central nervous system metastases: current approaches, challenges, and opportunities.

Cohen JV, Tawbi H, Margolin KA, Amravadi R, Bosenberg M, Brastianos PK, Chiang VL, de Groot J, Glitza IC, Herlyn M, Holmen SL, Jilaveanu LB, Lassman A, Moschos S, Postow MA, Thomas R, Tsiouris JA, Wen P, White RM, Turnham T, Davies MA, Kluger HM.

Pigment Cell Melanoma Res. 2016 Nov;29(6):627-642. doi: 10.1111/pcmr.12538. Epub 2016 Oct 22. Review.

19.

Use of Susceptibility-Weighted Imaging (SWI) in the Detection of Brain Hemorrhagic Metastases from Breast Cancer and Melanoma.

Franceschi AM, Moschos SJ, Anders CK, Glaubiger S, Collichio FA, Lee CB, Castillo M, Lee YZ.

J Comput Assist Tomogr. 2016 Sep-Oct;40(5):803-5. doi: 10.1097/RCT.0000000000000420.

20.

Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis.

Nishijima TF, Muss HB, Shachar SS, Moschos SJ.

Cancer Treat Rev. 2016 Apr;45:30-7. doi: 10.1016/j.ctrv.2016.02.006. Epub 2016 Mar 2. Review.

PMID:
26946217

Supplemental Content

Loading ...
Support Center